Effects of IGF-I and -II, IGF Binding Protein-3 (IGFBP-3), and Transforming Growth Factor-beta (TGF-beta) on Growth and Apoptosis of Human Osteosarcoma Saos-2/B-10 Cells: Lack of IGF-independent IGFBP-3 Effects
Overview
Authors
Affiliations
Objective: Insulin-like growth factor binding protein-3 (IGFBP-3) inhibits cell growth. Previous reports have suggested the existence of plasma membrane IGFBP-3 receptors that could mediate direct, IGF-independent effects. Thus far, however, the only well-defined putative IGFBP-3 receptor is the type V transforming growth factor-beta (TGF-beta) receptor, a membrane glycoprotein that mediates TGF-beta-induced growth inhibition in selected cells. The aim of the study was to test whether IGFBP-3 and TGF-beta exert short-term effects in an osteosarcoma cell line that produces no IGF but contains type 1 IGF receptors.
Design: DNA synthesis and apoptosis in Saos-2/B-10 cells were measured in response to IGF-I, IGF-II, IGFBP-3 and TGF-beta2, and to type 1 IGF receptor ligands with poor affinity for IGFBP-3 ([QAYL]-IGF-I and insulin).
Results: IGF-I and IGF-II stimulated thymidine incorporation into DNA and suppressed apoptosis in a dose-dependent manner with maximal effects at 1 and 3 nM respectively. TGF-beta2 slightly increased thymidine incorporation into DNA but had no effect on apoptosis. IGFBP-3 had no effect by itself. Whereas it blocked the above effects of 1 nmol/l IGF-I, it did not block those of 1 nmol/l [QAYL]-IGF-I or 100 nmol/l insulin.
Conclusions: IGFBP-3 does not affect DNA synthesis or apoptosis in an IGF-independent manner in IGF-responsive osteosarcoma cells. It therefore appears to act essentially by sequestration of IGF.
Zhang X, Jiang P, Wang C Front Oncol. 2023; 13:1127637.
PMID: 37746292 PMC: 10513387. DOI: 10.3389/fonc.2023.1127637.
Sergi C, Shen F, Liu S Front Endocrinol (Lausanne). 2019; 10:93.
PMID: 30881341 PMC: 6405434. DOI: 10.3389/fendo.2019.00093.
Schmid C, Ghirlanda C, Niessen M Mol Cell Biochem. 2017; 432(1-2):41-54.
PMID: 28316059 PMC: 5532423. DOI: 10.1007/s11010-017-2996-y.
Laway B Ther Adv Endocrinol Metab. 2015; 6(6):267-72.
PMID: 26623004 PMC: 4647133. DOI: 10.1177/2042018815603927.
Colciago A, Celotti F, Casati L, Giancola R, Castano S, Antonini G Int J Biomed Sci. 2013; 5(4):380-9.
PMID: 23675162 PMC: 3614801.